Eddy Pharmaceuticals Announcement on Participating in the 2024 Semi-Annual Science and Technology Innovation Board Special Group Performance Briefing on Pharmaceuticals and Biological Products
Eddy Pharmaceutical\'s announcement on applying for bank credit lines
Eddy Pharmaceuticals Investor Relations Activity Record Form (2024-003)
Announcement of the resolution of the 25th meeting of the Second Session of the Board of Directors of Jiangsu Aidea Pharmaceutical
Jiangsu Aidea Pharmaceutical Co., Ltd. verification report on the use of funds raised in the previous round
Announcement of the resolution of the 24th meeting of the second session of the Supervisory Board of Jiangsu Aidea Pharmaceutical
Jiangsu Aidea Pharmaceutical's explanation of the use of the raised funds in the technology innovation field.
Special report on the use of funds raised by Jiangsu Aidea Pharmaceutical
Special report on the deposit and actual use of the raised funds for the first half of 2024 by Jiangsu Aidea Pharmaceutical
Jiangsu Aidea Pharmaceutical's semi-annual assessment report on the "Quality Improvement and Efficiency Enhancement for Return" action plan for the company in 2024.
Announcement from Jiangsu Aidea Pharmaceutical regarding the penalties or regulatory measures imposed by the securities regulatory authorities and the stock exchange in the past five years.
Minsheng Securities Co., Ltd.'s independent financial advisor verification opinion on self-examination report on insider trading of Jiangsu Aidea Pharmaceutical Co., Ltd.'s stock transactions
Special inspection opinion on the self-examination report of insiders' trading of stocks related to the major asset purchase of Jiangsu Aidea Pharmaceutical Co., Ltd. by Jiangsu Century Tongren Law Firm
Announcement of Jiangsu Aidea Pharmaceutical's self-inspection report on insider trading related to this transaction involving the buying and selling of stocks.
Special inspection opinions on the inquiry letter regarding the significant asset purchase of Jiangsu Aidea Pharmaceutical Co., Ltd. by Shanghai Stock Exchange Securities Co., Ltd. issued by Minsheng Securities Co., Ltd.
Zhongsheng Evaluation Consulting Co., Ltd.'s special verification opinion on the Shanghai Stock Exchange's "Inquiry Letter on Major Asset Purchase Transactions of Jiangsu Aidea Pharmaceutical Co., Ltd."
Special examination opinion of Notary Tianye Certified Public Accountants on the inquiry letter of Shanghai Stock Exchange regarding the major asset purchase of Jiangsu Aidea Pharmaceutical Co., Ltd.
Review report and prepare financial statements for Jiangsu Aidea Pharmaceutical Co., Ltd.
Audit report from January 2022 to April 2024 for Nanjing Nanda Pharmaceutical Co., Ltd.
Supplementary legal opinion on the major asset restructuring of Jiangsu Aidea Pharmaceutical Co., Ltd. by Jiangsu Century Tungtien Law Firm (1)
No Data
No Data